GENEVA — For the final contact traced to the cruise ship that became the site of the world’s first maritime hantavirus emergency, the news arrived Wednesday: a negative test, a completed quarantine, a return home. Three months after the MV Hondius departed Argentina for one of the planet’s most remote island outposts, the World Health Organization declared the outbreak officially over.
Three of the 13 people who contracted the Andes hantavirus during that voyage did not survive.
“Today, the final contact of a person exposed to hantavirus on the cruise ship MV Hondius completed their quarantine period, tested negative and returned home,” WHO Director-General Tedros Adhanom Ghebreyesus said Wednesday. The declaration closed an event that, at its height, had public health authorities in 33 countries and territories monitoring more than 650 people who had been in contact with those infected, Al Jazeera reported.
The breadth of that response reflects something unusual about the Andes strain. Every other known hantavirus spreads from rodents to humans, typically through contact with infected animal waste. Andes is the lone exception: documented outbreaks in Argentina and Chile going back to the 1990s established that it can also transmit between people. That single distinction transformed what might have been a localized incident in the South Atlantic into a three-continent public health operation requiring coordinated quarantine monitoring across more than three dozen jurisdictions.
The MV Hondius, a Dutch-flagged expedition vessel operated by Oceanwide Expeditions, left Ushuaia, Argentina on April 1 on a voyage that included a stop at Tristan da Cunha, a volcanic island in the South Atlantic so isolated it holds the designation of the world’s most remote permanently inhabited settlement. The ship reached Rotterdam on May 18. The last case among those infected was reported May 25, and no further transmission chains were confirmed beyond the original passengers and crew.
How the initial infection began has not been established. Andes virus circulates in the long-tailed pygmy rice rat, a small rodent endemic to Patagonia and the southern Andes, and expedition passengers who go ashore in those regions occasionally encounter environments where such animals are present. Neither WHO nor the Dutch and Argentine health authorities who coordinated the initial response have publicly identified the source of the index case aboard the ship.
That unanswered question carries weight beyond this particular voyage. The MV Hondius was not a conventional leisure cruise. It was an expedition vessel: the kind that markets close contact with remote natural environments as its defining feature. Those environments, precisely because they are undisturbed by dense human settlement, are where pathogens like Andes hantavirus persist in animal populations. And expedition landings typically occur far from any hospital, making early clinical intervention difficult if a passenger sickens during or shortly after a shore excursion.
For WHO, Wednesday’s declaration represents something to measure against in the future. Health authorities successfully monitored more than 650 contacts across 33 countries over three months without a sustained second-generation transmission cluster forming outside the original shipboard population. The global coordination infrastructure that made this possible relies on advance notification protocols, bilateral health agreements, and cross-border data sharing among ministries. On Wednesday, it held.
The treatment picture is more sobering. There is no approved vaccine against any hantavirus. There is no targeted antiviral therapy for Andes infection. Clinicians caring for the three who died and the 10 who survived were limited to supportive care, the same approach used in South American hospitals that see Andes cases in endemic areas. That gap in the treatment arsenal is not unique to this outbreak: researchers only recently enrolled the first patients in an urgent clinical trial for Congo’s Bundibugyo Ebola strain, another virus with no approved drug and a death toll now above 440. Hantavirus pulmonary syndrome, the illness the Andes strain causes, typically develops one to eight weeks after exposure and carries an estimated case-fatality rate of 35 to 50 percent once symptoms appear.
WHO is now coordinating a clinical study across 21 countries to understand how the Andes strain behaves in patients with no prior hantavirus exposure, a category that includes nearly the entire population of Europe and most of Asia. The results are expected to inform clinical management protocols and, in the longer term, vaccine development priorities. Until those findings emerge, physicians treating imported Andes cases will be relying on data drawn from South American populations, who may differ immunologically from European patients in ways that are not yet understood.
The outbreak also exposed a gap in pre-voyage health screening that the expedition cruise industry has not addressed. Vessels now routinely visit Arctic, Antarctic, and sub-Antarctic destinations that were previously accessible only to research teams. The ecological zones those voyages traverse include hantavirus-endemic regions. Pre-departure screening for hantavirus exposure risk is not currently standard for passengers or crew departing from Patagonian ports, and no formal WHO-level health advisory specific to expedition cruising in hantavirus-endemic regions exists. In the United States, public health attention this summer has focused elsewhere: the country is tracking its highest early-season West Nile virus case count in two decades as the holiday weekend begins.
Whether Wednesday’s declaration prompts formal review of departure protocols for expedition cruises in South America is among the questions left open when the last contact tested negative and went home. Three others who boarded the MV Hondius in Ushuaia in April did not get that chance.
